Table 3.

Analyses of disease-free survival (surgically treated patients)

	Univariate			Multivariate
	RR	95% CI	P-value	RR	95% CI	P-value
Age (≤70 yrs)	1.05	0.39–2.56	.92	0.30	0.08–1.01	.05
Gender (male)	0.84	0.37–2.09	.70
Tumor site (head)	1.27	0.51–3.07	.60
Tumor size (≥30 mm)	3.37	1.36–8.35	.01	6.36	1.99–21.38	.01
Stage III (UICC)	2.18	0.50–6.66	.26
CEA (≥5 ng/mL)	1.75	0.61–4.39	.28
CA19-9 (≥37 mAU/mL)	2.96	1.14–9.16	.02	3.02	1.02–10.36	.05
Adjuvant chemotherapy	0.71	0.22–2.16	.54
Positive margin	1.25	0.36–3.45	.70
Plasma KRAS mutation	3.37	1.36–8.35	.01	3.58	1.36–9.60	.01

CEA, carcinoembryonic antigen; RR, relative risk; UICC, Union for International Cancer Control.